Stocks
Arcutis Biotherapeutics, Inc.ARQT
NASDAQHealthcareBiotechnology$22.75-0.70%
Focused on developing and commercializing treatments for immune-mediated dermatological diseases, this biopharmaceutical company has gained investor attention for its late-stage pipeline targeting conditions like psoriasis and atopic dermatitis. Its market valuation reflects optimism around potential FDA approvals for its topical therapies in underserved dermatology markets.
Market Cap: $2.8B52W Range: $11.86 – $31.77
Congressional Interest in Arcutis Biotherapeutics, Inc. (ARQT)
2 members of Congress have disclosed 5 trades in Arcutis Biotherapeutics, Inc. (ARQT), a Healthcare company. The buy/sell breakdown shows 3 purchases versus 2 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
5
Unique Politicians
2
Buys
3
Sells
2
Who in Congress Is Trading ARQT?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2026-03-03 | Gilbert Cisneros | buy | $1K – $15K |
| 2025-12-11 | Gilbert Cisneros | sell | $1K – $15K |